Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Carolyn Y. Fang, Jakub Svoboda, Adam D. Cohen, Henry C. Fung, Richard I. Fisher, Elizabeth Handorf, Hatcher Ballard, Stefan K. Barta, Daniel J. Landsburg, Dwivedy S. Nasta, Stephen J Schuster, Rashmi Khanal, Alexander W. MacFarlane, Kerry S. Campbell

Blood (2023) 142 (Supplement 1): 6526.

https://doi.org/10.1182/blood-2023-189330

Published: 2023

Journal Articles

Molecular Monitoring with Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

Shazia Nakhoda, Tamarrah Sklarz, Cheyenne Pagan, Matthew Matasar, Marcus Messmer, Zachary AK Frosch, Y. Lynn Wang, Asya Varshavsky Yanovsky, Rashmi Khanal, Carlyn Rose Tan, Henry C. Fung, Eli Mikkelsen, Kevin A. David, Mark Roschewski, Eric Ross, Allison P. Jacob, Erin Ahn, Nadia Khan

Blood (2023) 142 (Supplement 1): 6231.

https://doi.org/10.1182/blood-2023-179980

Published: 2023

Journal Articles

A Single Center Retrospective Analysis Comparing the Outcomes of Induction Therapy between 7+3 and FLAG-IDA/Venetoclax in Newly Diagnosed Patients with Acute Myeloid Leukemia

Peter Abdelmessieh, Asya Varshavsky-Yanovsky, Yuliya Shestovska, Rashmi Khanal, Michael Styler, Brittany Ballas, Forrest Ridgway, Michele Sorrentino, Anne Ojala, Henry C. Fung

Blood (2023) 142 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2023-174898

Published: 2023

Journal Articles

A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma

Stefan K. Barta, Tatyana A. Feldman, Jennifer A. DeSimone, Ellen Kim, Karthik Devajaran, Yibin Yang, Henry C. Fung, Tafseer Mahvish, Shazia Nakhoda, Nadia Khan

Blood (2022) 140 (Supplement 1): 6543–6544.

https://doi.org/10.1182/blood-2022-157201

Published: 2022

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model

Hongxing Sun, PhD, Shan He, PhD, Lijun Meng, PhD, Ying Wang, PhD, Hanghang Zhang, PhD, Yongnian Liu, Jian Wang, MD, Min Tao, MD, Stefan Klaus Barta, MD MRCP, MS, Essel D. Al-Saleem, MD, Henry C. Fung, FRCP, MBBChir, Jean-Pierre Issa, MD, Leizhen Zheng, MD, Yi Zhang, MD

Blood (2018) 132 (Supplement 1): 2050.

https://doi.org/10.1182/blood-2018-99-117354

Published: 2018

Journal Articles

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Jakub Svoboda, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MDMRCP,MS, Nadia Khan, MD, Henry C. Fung, FRCP,MBBChir, Carlyn Rose Tan, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Lauren Elizabeth Strelec, BA, Sarah J. Nagle, Steven M. Bair, MD, Sheryl Mitnick, MPH, RN, Terease S. Waite, PhD RN, MBE, Rachel Lynn Sargent, MD, Agata M. Bogusz, MDPhD, Ziver Sahin, MD, Anthony R. Mato, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 191.

https://doi.org/10.1182/blood.V130.Suppl_1.191.191

Published: 2017

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation

Henry C. Fung, FRCP, MD, Muhammed Alikhan, Lela Buckingham, PhD, John J. Maciejewski, MD, PhD, Reem Karmali, MD, Kent W Christopherson, II, PhD, Elizabeth Shima Rich, MD, PhD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Sunita Nathan, MD

Blood (2012) 120 (21): 4162.

https://doi.org/10.1182/blood.V120.21.4162.4162

Published: 2012

Journal Articles

Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,

Nelson J. Chao, MD, Daniel T Grima, M.Sc., George Carrum, MD, Leona Holmberg, MD., PhD, Henry C. Fung, FRCP, MD, Stephen Brown, Ph.D., Mitchell E. Horwitz, MD, Lisa M Bernard, M.Sc., Junya Kanda, MD, Jane L. Liesveld, MD, Brian McClune, DO, Paul Shaughnessy, MD, Guido J. Tricot, MD, PhD

Blood (2011) 118 (21): 4048.

https://doi.org/10.1182/blood.V118.21.4048.4048

Published: 2011

Journal Articles

Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,

Jennifer Tornatta, MS, ANP, John J. Maciejewski, MD, PhD, Sunita Nathan, MD, Bruce Mcleod, MD, Sridevi Palaparthy, MBA, MS, Elizabeth Shima Rich, MD, PhD, Kent W Christopherson, II, PhD, Stephanie A. Gregory, MD, Henry C. Fung, FRCP, MD

Blood (2011) 118 (21): 4061.

https://doi.org/10.1182/blood.V118.21.4061.4061

Published: 2011

Journal Articles

A Long-Term Follow-up Report on Autologous Hematopoetic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma — Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,

Henry C. Fung, FRCP, MD, Sunita Nathan, MD, Neel B. Shah, MD, John J. Maciejewski, MD, PhD, Elizabeth Shima Rich, MD, PhD, Jennifer Tornatta, MS, ANP, Nancy Licciardi, Parameswaran Venugopal, MD, Reem Karmali, MD, Stephanie A. Gregory, MD

Blood (2011) 118 (21): 4205.

https://doi.org/10.1182/blood.V118.21.4205.4205

Published: 2011

Journal Articles

Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends

Nelson J. Chao, MD, Lisa M Bernard, M.Sc., George Carrum, MD, Henry C. Fung, FRCP, MD, Daniel T Grima, M.Sc., Leona Holmberg, MD., PhD, Stephen Brown, Ph.D., Mitchell E. Horwitz, MD, Junya Kanda, MD, Jane L. Liesveld, MD, Brian McClune, DO, Paul Shaughnessy, MD, Guido J. Tricot, MD, PhD

Blood (2011) 118 (21): 1925.

https://doi.org/10.1182/blood.V118.21.1925.1925

Published: 2011

Journal Articles

CD26 Inhibition Preferentially Enhances In Vitro Migration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts.

Eun-Sun Yoo, MD, PhD, Sucheta Jagan, MS, Sridevi Palaparthy, MBA, MS, Mary A Enriquez, RN, ANP, Karen Samuels, RN, MS, NP-C, Sarah Walters, RN, MSN, GNP-BC, APN, Elizabeth Mieras, MMS, PA-C, Laura A Paganessi, MA, Chu-Myong Seong, MD, Elizabeth Shima Rich, MD, PhD, Henry C. Fung, FRCP, MD, Kent W. Christopherson, II, PhD

Blood (2010) 116 (21): 3714.

https://doi.org/10.1182/blood.V116.21.3714.3714

Published: 2010

Journal Articles

Update on a Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front Line Therapy for Patients with Indolent Lymphomas

Reem Karmali, MD, Mohamad Kassar, MD, Antonio M. Jimenez, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD, Henry C. Fung, FRCP, MD, Robert Bayer, MD, Teresa O'Brien, Stephanie Gregory, MD

Blood (2010) 116 (21): 3946.

https://doi.org/10.1182/blood.V116.21.3946.3946

Published: 2010

Journal Articles

Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study

Anas Younes, R. Gregory Bociek, John Kuruvilla, Pierre Laneuville, Henry C. Fung, Michel Drouin, Tracy Patterson, Jeffrey Besterman, Robert E. Martell

Blood (2010) 116 (21): 1763.

https://doi.org/10.1182/blood.V116.21.1763.1763

Published: 2010

Journal Articles

Cytokine Treatment of CD34 + Cord Blood Cells with G-CSF, GM-CSF, or SCF During 48 Hours of Ex Vivo Culture Alters CD26/DPPIV Peptidase Activity and Subsequent Engraftment Into NSG Immunodeficient Mice.

Laura A Paganessi, MA, Lydia Luy Tan, BS, Sucheta Jagan, MS, Robin Frank, BS, Antonio M. Jimenez, MD, Elizabeth Shima Rich, MD, PhD, Sunita Nathan, MD, John Maciejewski, MD, PhD, Henry C. Fung, FRCP, MD, Kent W. Christopherson, II, PhD

Blood (2010) 116 (21): 1460.

https://doi.org/10.1182/blood.V116.21.1460.1460

Published: 2010

Journal Articles

Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.

Antonio M. Jimenez, MD, George Behrens, MD, John Maciejewski, MD, PhD, Norman Wool, MD, Elizabeth Shima Rich, MD, PhD, Reem Karmali, MD, Parameswaran Venugopal, MD, Stephanie A. Gregory, MD, Henry C. Fung, FRCP, MD, Sunita Nathan, MD

Blood (2010) 116 (21): 1283.

https://doi.org/10.1182/blood.V116.21.1283.1283

Published: 2010

Journal Articles

The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.

Catherine Veeder, MD, Sheila Davies, R.N., OCN, Christina Havey, R.N., John J. Maciejewski, MD, PhD, Sunita Nathan, MD, Stephanie A. Gregory, MD, Parameswaran Venugopal, MD, Jamile Shammo, MD, Henry C. Fung, MD

Blood (2009) 114 (22): 4346.

https://doi.org/10.1182/blood.V114.22.4346.4346

Published: 2009

Journal Articles

Efficacy of Administration of Plerixafor (Mozobil®) at 5:00 PM for Stem Cell Mobilization (SCM) in Patients Receiving Autologous Stem Cell Transplant.

Jennifer Tornatta, RN, MSN, ANP-BC, John J. Maciejewski, MD, PhD, Sunita Nathan, MD, Bruce C. McLeod, MD, Darilyn Rhoades, RN, Sridevi Palaparthy, MBA, MS, Henry C. Fung

Blood (2009) 114 (22): 3218.

https://doi.org/10.1182/blood.V114.22.3218.3218

Published: 2009

NARROW

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Molecular Monitoring with Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma

A Single Center Retrospective Analysis Comparing the Outcomes of Induction Therapy between 7+3 and FLAG-IDA/Venetoclax in Newly Diagnosed Patients with Acute Myeloid Leukemia

A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation

Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,

Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,

A Long-Term Follow-up Report on Autologous Hematopoetic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma — Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,

Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends

CD26 Inhibition Preferentially Enhances In Vitro Migration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts.

Update on a Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front Line Therapy for Patients with Indolent Lymphomas

Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study

Cytokine Treatment of CD34 + Cord Blood Cells with G-CSF, GM-CSF, or SCF During 48 Hours of Ex Vivo Culture Alters CD26/DPPIV Peptidase Activity and Subsequent Engraftment Into NSG Immunodeficient Mice.

Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.

The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.

Efficacy of Administration of Plerixafor (Mozobil®) at 5:00 PM for Stem Cell Mobilization (SCM) in Patients Receiving Autologous Stem Cell Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only